Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Telephone Support to Improve Adherence to Anti-HIV Medications

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
AIDS Clinical Trials Group
ClinicalTrials.gov Identifier:
NCT00988442
First received: October 1, 2009
Last updated: December 5, 2013
Last verified: December 2013

October 1, 2009
December 5, 2013
October 2010
February 2013   (final data collection date for primary outcome measure)
Virologic suppression, defined as HIV-1 RNA at less than 200 copies/mL [ Time Frame: Measured at Week 48 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00988442 on ClinicalTrials.gov Archive Site
  • Antiretroviral (ARV) medication adherence [ Time Frame: Measured at Weeks 12, 24, 48, and 72 ] [ Designated as safety issue: No ]
  • Time to antiretroviral therapy (ART) regimen discontinuation [ Time Frame: Measured throughout ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: Measured at Weeks 24, 48, and 72 ] [ Designated as safety issue: No ]
  • CD4 cell count [ Time Frame: Measured at Weeks 12, 24, 48, and 72 ] [ Designated as safety issue: No ]
  • Cost of the adherence telephone interventions, if the intervention is successful [ Time Frame: Measured at Week 48 ] [ Designated as safety issue: No ]
  • Symptom distress, illness events, or mortality [ Time Frame: Measured throughout the study ] [ Designated as safety issue: Yes ]
  • Virologic suppression, defined as HIV-1 RNA less than 1,000 copies/mL [ Time Frame: Measured at Week 48 ] [ Designated as safety issue: No ]
  • Virological suppression, measured as both HIV-1 RNA less than 200 and less than 1,000 copies/mL [ Time Frame: Measured at Weeks 12, 24, and 72 ] [ Designated as safety issue: No ]
  • Time to virologic failure, with virologic failure defined as confirmed HIV-1 RNA of at least 200 copies/mL at or after 24 weeks [ Time Frame: Measured at Weeks 24, 48, and 72 ] [ Designated as safety issue: No ]
  • Time to first virological suppression, defined as HIV-1 RNA less than 200 copies/mL [ Time Frame: Measured at Weeks 12, 24, 48, and 72 ] [ Designated as safety issue: No ]
  • Time to discontinuation of enhanced nursing telephone adherence intervention [ Time Frame: Measured throughout ] [ Designated as safety issue: No ]
  • Intervention dosage score for enhanced nursing telephone support, including total percentage of scheduled calls successfully delivered and total amount of time spent in calls [ Time Frame: Measured at Week 72 ] [ Designated as safety issue: No ]
  • Antiretroviral (ARV) medication adherence [ Time Frame: Measured at Weeks 12, 24, 48, and 72 ] [ Designated as safety issue: No ]
  • Time to antiretroviral therapy (ART) regimen discontinuation [ Time Frame: Measured throughout ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: Measured at Weeks 24, 48, and 72 ] [ Designated as safety issue: No ]
  • CD4 cell count [ Time Frame: Measured at Weeks 12, 24, 48, and 72 ] [ Designated as safety issue: No ]
  • Cost of the adherence telephone interventions, if the intervention is successful [ Time Frame: Measured at Week 48 ] [ Designated as safety issue: No ]
  • Symptom distress, illness events, or mortality [ Time Frame: Measured throughout the study ] [ Designated as safety issue: Yes ]
  • Virologic suppression, defined as HIV-1 RNA less than 1,000 copies/mL [ Time Frame: Measured at Week 48 ] [ Designated as safety issue: No ]
  • Virological suppression, defined as both HIV-1 RNA less than 200 and less than 1,000 copies/mL [ Time Frame: Measured at Weeks 12, 24, and 72 ] [ Designated as safety issue: No ]
  • Time to virologic failure, with virologic failure defined as confirmed HIV-1 RNA of at least 200 copies/mL at or after 24 weeks [ Time Frame: Measured on Weeks 24, 48, and 72 ] [ Designated as safety issue: No ]
  • Time to first virological suppression, defined as HIV-1 RNA less than 200 copies/mL [ Time Frame: Measured at Weeks 12, 24, 48, and 72 ] [ Designated as safety issue: No ]
  • Time to discontinuation of enhanced nursing telephone adherence intervention [ Time Frame: Measured throughout ] [ Designated as safety issue: No ]
  • Intervention dosage score for enhanced nursing telephone support, including total percentage of scheduled calls successfully delivered and total amount of time spent in calls [ Time Frame: Measured at Week 72 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Telephone Support to Improve Adherence to Anti-HIV Medications
A Randomized Trial of Enhanced Nursing Telephone Support to Improve Medication Self-Management and Viral Outcomes of Antiretroviral Therapy-Experienced Patients

This study will test a system of nursing telephone support to see if it improves adherence to antiretroviral therapy (ART) in at-risk, treatment-experienced people.

Antiretroviral therapy (ART) is only successful in treating HIV when people take all the medications prescribed to them when and how they are instructed. However, a third or more of patients on ART are not able to adhere to their medication regimens. Therefore, making sure that these patients stay healthy involves making sure they are motivated and informed about the importance of adhering to their ART. Nurses can deliver interventions to motivate and inform patients through regularly scheduled phone calls. These calls allow nurses to check in between clinic visits, are convenient to patients, and are cost efficient. This study will test an enhanced telephone support intervention provided by nurses that aims to improve ART adherence and treatment outcomes.

Participation in this study will last 48 weeks, with follow-up lasting 72 weeks. Participants will be randomly assigned to receive either care as usual or the enhanced telephone support intervention plus care as usual. The telephone support intervention will involve phone calls made weekly for the first 8 weeks of the study and then every 2 weeks for the next 40 weeks. Nurses will make these calls at a time and place participants choose. During the calls, nurses will provide information, motivational enhancement, and problem-solving skills.

Study assessments will take place at study entry and after 12, 24, 48, and 72 weeks. Assessments will measure CD4 cell count, HIV viral load, adherence, and illness events. Adherence will be measured through questionnaires and an electronic pill cap.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
HIV Infections
  • Behavioral: Enhanced nursing telephone support
    Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses may schedule more frequent calls at their discretion. Calls will provide information, motivational enhancement, problem-solving skills, and affective support.
  • Behavioral: Standard care
    Care as usual for participants starting a new ART regimen; this may vary by study site.
  • Experimental: Enhanced nursing telephone support with standard care
    Participants will receive enhanced nursing telephone support plus care as usual.
    Interventions:
    • Behavioral: Enhanced nursing telephone support
    • Behavioral: Standard care
  • Active Comparator: Standard care
    Participants will receive care as usual.
    Intervention: Behavioral: Standard care

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
59
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Enrollment in an AIDS Clinical Trials Group (ACTG) treatment study that is an approved A5251 parent or coenrolling partner study
  • Virologic failure on combination antiretroviral therapy (ART), with an HIV-1 genotype conducted on or soon after the failure, within 16 weeks prior to entry. HIV-1 genotype results must be available at entry.
  • History of prior nonadherence to ART during the past year documented either by patient self-report or recorded in the patient's medical record
  • Most recent HIV-1 RNA value of at least 400 copies/mL, obtained within 90 days prior to study entry and measured using any FDA-approved test for quantifying HIV-1 RNA
  • Initiating a new ART regimen within 3 days after randomization with two or more new antiretroviral (ARV) medications to which the participant is expected to be susceptible based on HIV-1 genotype, as specified in the parent or coenrolling partner study or determined by the site investigator. The regimen must be selected for the participant prior to the time of randomization for A5251.
  • Ability to have CD4+ cell count and plasma HIV-1 RNA assays as a component of the parent or coenrolling partner study or per other mechanism. Only HIV-1 RNA at week 48 and confirmation of virologic failure will be collected by A5251, unless collected by the parent or coenrolling partner study per exact A5251 specifications.

Exclusion Criteria:

  • No regular access to a phone. Candidates without phones may elect to participate by calling the HIV nurse specialists using an 800 number, rather than being called by the HIV nurse specialist.
  • Coenrollment in another adherence trial, unless approved by the A5251 study chair
  • Current incarceration
  • Any condition that, in the opinion of the site investigator, would compromise the candidate's ability to participate in the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT00988442
ACTG A5251, 1U01AI068636, 10632
Yes
AIDS Clinical Trials Group
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)
Study Chair: Nancy R. Reynolds, PhD, RN, NP Yale University School of Nursing
AIDS Clinical Trials Group
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP